These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 6806156)

  • 1. Plasmapheresis: its value in the management of patients with antibodies to factor VIII.
    Francesconi M; Korninger C; Thaler E; Niessner H; Höcker P; Lechner K
    Haemostasis; 1982; 11(2):79-86. PubMed ID: 6806156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serial plasmapheresis in a haemophiliac with antibodies to FVIII.
    Cobcroft R; Tamagnini G; Dormandy KM
    J Clin Pathol; 1977 Aug; 30(8):763-5. PubMed ID: 599190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoradiometric assay of VIII:CAg, a potential tool to detect human anti-VIII:C antibodies.
    Hellings JA; van Leeuwen FR; Over J; van Mourik JA
    Thromb Res; 1982 May; 26(4):297-302. PubMed ID: 6810499
    [No Abstract]   [Full Text] [Related]  

  • 4. Experience with factor VIII: C inhibitors and acquired von Willebrand's disease in an adult at Ramathibodi Hospital.
    Angchaisuksiri P; Atichartakarn V; Pathepchotiwong K; Jootar S; Ungkanont A; Chuncharunee S
    Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():152-8. PubMed ID: 7886560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Control of life-threatening bleeding by combined plasmapheresis and immunosuppressive treatment in a haemophiliac with inhibitors.
    Révész T; Mátyus J; Goldschmidt B; Harsanyi V
    Arch Dis Child; 1980 Aug; 55(8):641-3. PubMed ID: 6776907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current status and trends in the treatment of hemophilic patients with inhibitors.
    Bloom AL
    Prog Clin Biol Res; 1981; 72():123-38. PubMed ID: 6801682
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of factor VIII inhibitors.
    Kasper CK
    Prog Hemost Thromb; 1989; 9():57-86. PubMed ID: 2492380
    [No Abstract]   [Full Text] [Related]  

  • 8. Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity.
    Oldenburg J; Lacroix-Desmazes S; Lillicrap D
    Haematologica; 2015 Feb; 100(2):149-56. PubMed ID: 25638804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is a change of factor VIII product a risk factor for the development of a factor VIII inhibitor?
    Baglin T; Beacham E
    Thromb Haemost; 1998 Dec; 80(6):1036-7. PubMed ID: 9869186
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of treatment with activated prothrombin complex concentrate (FEIBA) on factor VIII-antibody level.
    Lechner K; Nowotny C; Krinninger B; Zegner M; Deutsch E
    Thromb Haemost; 1979 Feb; 40(3):478-85. PubMed ID: 425062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Factor VIII inhibitors].
    Ruggeri ZM; Bader R; Coppola R; Mannuccio Mannucci P
    Ric Clin Lab; 1977; 7 Suppl 2():17-29. PubMed ID: 339315
    [No Abstract]   [Full Text] [Related]  

  • 12. Electrophoretic heterogeneity of normal factor VIII/Von Willebrand protein, and abnormal electrophoretic mobility in patients with Von Willebrand's disease.
    Sultan Y; Simeon J; Caen JP
    J Lab Clin Med; 1976 Feb; 87(2):185-94. PubMed ID: 1082003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitor antibody development and T cell response to human factor VIII in murine hemophilia A.
    Qian J; Borovok M; Bi L; Kazazian HH; Hoyer LW
    Thromb Haemost; 1999 Feb; 81(2):240-4. PubMed ID: 10063999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered serum factor VIII-related antigen (VIII : AGN)/von Willebrand factor (VIII : vWf) in haemophiliacs with inhibitors to factor VIII procoagulant activity (VIII : C).
    Ballard JO; Sanders JC; Eyster ME
    Thromb Haemost; 1981 Feb; 45(1):68-72. PubMed ID: 6166064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Studies on the usefulness of double filtration plasmapheresis in a hemophilia A patient with anti-factor VIII antibody (inhibitor)].
    Okubo S; Ikuma T; Hamaguchi Y; Yasunaga K
    Rinsho Ketsueki; 1985 May; 26(5):701-8. PubMed ID: 3932716
    [No Abstract]   [Full Text] [Related]  

  • 16. [Successful treatment of acquired F:VIII C inhibitor after delivery using plasmapheresis and high doses of immunoglobulins].
    Belić A; Pejin D; Canak V; Felle D; Lucić A
    Med Pregl; 1994; 47(9-10):359-61. PubMed ID: 7565328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a F.VIII epitope recognized by a human hemophilic inhibitor.
    Lubahn BC; Ware J; Stafford DW; Reisner HM
    Blood; 1989 Feb; 73(2):497-9. PubMed ID: 2465036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pattern of factor VIII inhibitors in patients with hemophilia A in the north east of Iran.
    Modaresi AR; Torghabeh HM; Pourfathollah AA; Shooshtari MM; Yazdi ZR
    Hematology; 2006 Jun; 11(3):215-7. PubMed ID: 17325965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Successful treatment of massive hemorrhagic diathesis caused by Factor VIII:C-antibodies with adsorption plasmapheresis and immunosuppression].
    Mondorf W; Grützmacher P; Schmidt H; Wolff B; Scharrer I; von Baum H
    Med Klin (Munich); 1991 Mar; 86(3):165-70, 171. PubMed ID: 1903498
    [No Abstract]   [Full Text] [Related]  

  • 20. Disappearance of factor VIII:C antibodies in patients with haemophilia A upon frequent administration of factor VIII in intermediate or low dose.
    Van Leeuwen EF; Mauser-Bunschoten EP; Van Dijken PJ; Kok AJ; Sjamsoedin-Visser EJ; Sixma JJ
    Br J Haematol; 1986 Oct; 64(2):291-7. PubMed ID: 3096366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.